| |
| |
|
| Insider
Information: |
Matsuda Masaru |
| Relationship: |
See Remark |
| City: |
San Diego |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
2 |
|
| Direct
Shares |
210,473 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$2,386,181 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
210,473 |
|
|
| Total
Value |
$2,386,181 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
|
|
| Stock
price went down : |
|
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Halozyme Therapeutics Inc |
HALO |
SVP, General Counsel |
2021-09-04 |
20,049 |
|
0 |
Premium* |
|
|
Arcutis Biotherapeutics, Inc. |
ARQT |
See Remark |
2024-03-04 |
190,424 |
2022-03-03 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| ARQT |
Arcutis Biotherapeutics, ... |
See Remark |
• – – |
2024-03-04 |
4 |
AS |
$11.12 |
$41,816 |
D/D |
(3,760) |
190,424 |
0 |
% |
|
| ARQT |
Arcutis Biotherapeutics, ... |
See Remark |
• – – |
2024-02-13 |
4 |
A |
$0.00 |
$0 |
D/D |
119,550 |
194,184 |
0 |
- |
|
| ARQT |
Arcutis Biotherapeutics, ... |
See Remark |
• – – |
2024-01-12 |
4 |
A |
$0.00 |
$0 |
D/D |
28,000 |
74,634 |
0 |
- |
|
| ARQT |
Arcutis Biotherapeutics, ... |
See Remark |
• – – |
2023-11-21 |
4 |
S |
$1.98 |
$3,661 |
D/D |
(1,850) |
46,634 |
0 |
% |
|
| ARQT |
Arcutis Biotherapeutics, ... |
See Remark |
• – – |
2023-11-18 |
4 |
A |
$0.00 |
$0 |
D/D |
4,875 |
48,484 |
0 |
- |
|
| ARQT |
Arcutis Biotherapeutics, ... |
See Remark |
• – – |
2023-05-31 |
4 |
S |
$7.80 |
$14,278 |
D/D |
(1,830) |
42,146 |
0 |
% |
|
| ARQT |
Arcutis Biotherapeutics, ... |
See Remark |
• – – |
2023-05-31 |
4 |
A |
$6.38 |
$9,334 |
D/D |
1,463 |
43,609 |
0 |
- |
|
| ARQT |
Arcutis Biotherapeutics, ... |
See Remark |
• – – |
2023-05-27 |
4 |
A |
$0.00 |
$0 |
D/D |
4,875 |
43,976 |
0 |
- |
|
| ARQT |
Arcutis Biotherapeutics, ... |
See Remarks |
• – – |
2023-03-02 |
4 |
A |
$0.00 |
$0 |
D/D |
21,000 |
39,101 |
0 |
- |
|
| ARQT |
Arcutis Biotherapeutics, ... |
See Remarks |
• – – |
2023-03-02 |
4 |
AS |
$15.82 |
$22,696 |
D/D |
(1,434) |
18,101 |
0 |
% |
|
| ARQT |
Arcutis Biotherapeutics, ... |
See Remark |
• – – |
2022-11-21 |
4 |
S |
$18.19 |
$31,289 |
D/D |
(1,720) |
19,535 |
0 |
% |
|
| ARQT |
Arcutis Biotherapeutics, ... |
See Remark |
• – – |
2022-11-18 |
4 |
A |
$0.00 |
$0 |
D/D |
4,875 |
21,255 |
0 |
- |
|
| ARQT |
Arcutis Biotherapeutics, ... |
SVP and General Counsel |
• – – |
2022-06-02 |
4 |
S |
$19.73 |
$35,419 |
D/D |
(1,795) |
16,380 |
0 |
% |
|
| ARQT |
Arcutis Biotherapeutics, ... |
SVP and General Counsel |
• – – |
2022-05-27 |
4 |
A |
$0.00 |
$0 |
D/D |
4,875 |
18,175 |
0 |
- |
|
| ARQT |
Arcutis Biotherapeutics, ... |
SVP and General Counsel |
• – – |
2022-03-03 |
4 |
A |
$0.00 |
$0 |
D/D |
13,300 |
13,300 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
SVP, General Counsel |
• – – |
2021-09-04 |
4 |
D |
$42.22 |
$144,055 |
D/D |
(3,412) |
20,049 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
SVP, General Counsel |
• – – |
2021-09-04 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,883 |
23,461 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
SVP, General Counsel |
• – – |
2021-02-12 |
4 |
D |
$49.84 |
$102,022 |
D/D |
(2,047) |
16,578 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
SVP, General Counsel |
• – – |
2021-02-12 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,129 |
18,625 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
SVP, General Counsel |
• – – |
2021-02-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,257 |
17,699 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
SVP, General Counsel |
• – – |
2021-02-10 |
4 |
D |
$50.60 |
$162,072 |
D/D |
(3,203) |
14,496 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
SVP, General Counsel |
• – – |
2020-09-04 |
4 |
D |
$27.70 |
$65,926 |
D/D |
(2,380) |
11,442 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
SVP, General Counsel |
• – – |
2020-09-04 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,884 |
13,822 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
SVP, General Counsel |
• – – |
2020-02-12 |
4 |
D |
$20.00 |
$33,620 |
D/D |
(1,681) |
6,938 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
SVP, General Counsel |
• – – |
2020-02-12 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,130 |
8,619 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
